Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan

Company’s Stock Plunged In Absence Of M&A Deal

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.

Finance Watch Public Company
• Source: Alamy

Cytokinetics, Inc. CEO Robert Blum has maintained since the company reported positive topline Phase III results for the cardiac myosin inhibitor aficamten in obstructive hypertrophic cardiomyopathy (oHCM) in December that it is capable of commercializing the drug on its own. But even without a deal announcement in the ensuing months, including after it presented detailed SEQUOIA-HCM results earlier this month, investors have held out hope that a big pharma would step up to buy Cytokinetics in a multibillion-dollar deal.

[Sidebar#SC150249]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.